216 related articles for article (PubMed ID: 30287318)
1. The role of TERT promoter mutations in differentiating recurrent nevi from recurrent melanomas: A retrospective, case-control study.
Walton KE; Garfield EM; Zhang B; Quan VL; Shi K; Mohan LS; Haugh AM; VandenBoom T; Yazdan P; Isales MC; Panah E; Gerami P
J Am Acad Dermatol; 2019 Mar; 80(3):685-693. PubMed ID: 30287318
[TBL] [Abstract][Full Text] [Related]
2. Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.
Thomas NE; Edmiston SN; Tsai YS; Parker JS; Googe PB; Busam KJ; Scott GA; Zedek DC; Parrish EA; Hao H; Slater NA; Pearlstein MV; Frank JS; Kuan PF; Ollila DW; Conway K
Am J Dermatopathol; 2019 Apr; 41(4):264-272. PubMed ID: 30211730
[TBL] [Abstract][Full Text] [Related]
3. TERT Promoter Mutational Analysis as an Ancillary Diagnostic Tool for Diagnostically Challenging Melanocytic Neoplasms.
Boutko A; Asadbeigi S; Roth A; Lampley N; Olivares S; Dittmann D; Dittmann D; Jennings L; Gerami P
Am J Dermatopathol; 2023 May; 45(5):289-299. PubMed ID: 36898007
[TBL] [Abstract][Full Text] [Related]
4. Recurrent melanocytic nevi and melanomas in dermoscopy: results of a multicenter study of the International Dermoscopy Society.
Blum A; Hofmann-Wellenhof R; Marghoob AA; Argenziano G; Cabo H; Carrera C; Costa Soares de Sá B; Ehrsam E; González R; Malvehy J; Manganoni AM; Puig S; Simionescu O; Tanaka M; Thomas L; Tromme I; Zalaudek I; Kittler H
JAMA Dermatol; 2014 Feb; 150(2):138-45. PubMed ID: 24226788
[TBL] [Abstract][Full Text] [Related]
5. PRAME Immunohistochemical Expression and TERT Promoter Mutational Analysis as Ancillary Diagnostic Tools for Differentiating Proliferative Nodules From Melanoma Arising in Congenital Nevi.
Boutko A; Hagstrom M; Lampley N; Roth A; Olivares S; Dhillon S; Fumero-Velázquez M; Benton S; Zhao J; Zhang B; Dittmann D; Asadbeigi S; Busam KJ; Gerami P
Am J Dermatopathol; 2023 Jul; 45(7):437-447. PubMed ID: 37338065
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations in atypical melanocytic lesions: A series of seven cases with adverse melanoma-specific outcome.
Huber R; Lee J; Borretta L; Tessier-Cloutier B; Lum A; Yip S; Horst BA
Hum Pathol; 2024 Feb; 144():34-39. PubMed ID: 38224873
[TBL] [Abstract][Full Text] [Related]
8. TERT and TERT promoter in melanocytic neoplasms: Current concepts in pathogenesis, diagnosis, and prognosis.
Motaparthi K; Kim J; Andea AA; Missall TA; Novoa RA; Vidal CI; Fung MA; Emanuel PO
J Cutan Pathol; 2020 Aug; 47(8):710-719. PubMed ID: 32202662
[TBL] [Abstract][Full Text] [Related]
9. Genetic Background of Iris Melanomas and Iris Melanocytic Tumors of Uncertain Malignant Potential.
van Poppelen NM; Vaarwater J; Mudhar HS; Sisley K; Rennie IG; Rundle P; Brands T; van den Bosch QCC; Mensink HW; de Klein A; Kiliç E; Verdijk RM
Ophthalmology; 2018 Jun; 125(6):904-912. PubMed ID: 29371009
[TBL] [Abstract][Full Text] [Related]
10. Recurrent nevus phenomenon: a clinicopathologic study of 357 cases and histologic comparison with melanoma with regression.
King R; Hayzen BA; Page RN; Googe PB; Zeagler D; Mihm MC
Mod Pathol; 2009 May; 22(5):611-7. PubMed ID: 19270643
[TBL] [Abstract][Full Text] [Related]
11. Common acquired melanocytic nevi, melanocytic dysplasia and malignant melanoma. A morphometric study.
Santucci M; Urso C; Giannini A; Bondi R
Appl Pathol; 1989; 7(2):111-5. PubMed ID: 2730799
[TBL] [Abstract][Full Text] [Related]
12. Common and uncommon melanocytic nevi and borderline melanomas.
Reed RJ; Ichinose H; Clark WH; Mihm MC
Semin Oncol; 1975 Jun; 2(2):119-47. PubMed ID: 1234372
[No Abstract] [Full Text] [Related]
13. Development of a novel noninvasive adhesive patch test for the evaluation of pigmented lesions of the skin.
Gerami P; Alsobrook JP; Palmer TJ; Robin HS
J Am Acad Dermatol; 2014 Aug; 71(2):237-44. PubMed ID: 24906614
[TBL] [Abstract][Full Text] [Related]
14. Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi.
Fan Y; Lee S; Wu G; Easton J; Yergeau D; Dummer R; Vogel P; Kirkwood JM; Barnhill RL; Pappo A; Bahrami A
J Invest Dermatol; 2016 Jan; 136(1):339-342. PubMed ID: 26763461
[No Abstract] [Full Text] [Related]
15. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma.
van Dijk MC; Bernsen MR; Ruiter DJ
Am J Surg Pathol; 2005 Sep; 29(9):1145-51. PubMed ID: 16096402
[TBL] [Abstract][Full Text] [Related]
16. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
17. Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool.
Bauer J; Bastian BC
Dermatol Ther; 2006; 19(1):40-9. PubMed ID: 16405569
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic utility of PRAME and p16 in distinguishing nodal nevi from nodal metastatic melanoma.
See SHC; Finkelman BS; Yeldandi AV
Pathol Res Pract; 2020 Sep; 216(9):153105. PubMed ID: 32825968
[TBL] [Abstract][Full Text] [Related]
19. Human telomerase RNA component expression in Spitz nevi, common melanocytic nevi, and malignant melanomas.
Guttman-Yassky E; Bergman R; Manov L; Sprecher E; Shaefer Y; Kerner H
J Cutan Pathol; 2002 Jul; 29(6):341-6. PubMed ID: 12135464
[TBL] [Abstract][Full Text] [Related]
20. Recurrent pigmented melanocytic nevus. A benign lesion, not to be mistaken for malignant melanoma.
Sexton M; Sexton CW
Arch Pathol Lab Med; 1991 Feb; 115(2):122-6. PubMed ID: 1992976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
